ZangS, PontoKA, KahalyGJ. 2011. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab, 96:320–332.
2.
BartalenaL, BaldeschiL, DickinsonA, EcksteinA, Kendall-TaylorP, MarcocciC, MouritsM, PerrosP, BoboridisK, BoschiA, CurròN, DaumerieC, KahalyGJ, KrassasGE, LaneCM, LazarusJH, MarinòM, NardiM, NeohC, OrgiazziJ, PearceS, PincheraA, PitzS, SalviM, SivelliP, StahlM, von ArxG, WiersingaWM. 2008. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol, 158:273–285.
3.
DinsenS, BaslundB, KloseM, RasmussenAK, Friis-HansenL, HilstedL, Feldt-RasmussenU. 2013. Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med, 24:714–720.
4.
ChrousosGP, KinoT, CharmandariE. 2009. Evaluation of the hypothalamic–pituitary–adrenal axis function in childhood and adolescence. Neuroimmunomodulation, 16:272–283.
